{"success":true,"data":{"pressRelease":{"id":"30121","rtpr_id":"nBw1C23tMa","ticker":"LLY","exchange":"NYSE","all_tickers":["LLY","260Y"],"title":"Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA","author":"Business Wire","published_at":"2026-05-11T16:43:00.180Z","article_body":"Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC\nInvestigates Adequacy of Price and Process in Proposed Sale of Centessa\nPharmaceuticals plc - CNTA\n\nFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law\nfirm of Kahn Swick & Foti\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com%2F&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=Kahn+Swick+%26amp%3B+Foti&index=1&md5=12d2e9ac3e8743bd5987953e4d50830a)\n, LLC (“KSF”) are investigating the proposed sale of Centessa\nPharmaceuticals\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-cnta%2F&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=Centessa+Pharmaceuticals&index=2&md5=6f6416b8ec8eaac673eb5ba2fe73b6b3)\nplc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of\nthe proposed transaction, shareholders of Centessa will receive $38.00 in cash\nper share plus one non-transferrable contingent value right entitling the\nholder to receive up to an aggregate of $9.00 subject to the achievement of\ncertain milestones. KSF is seeking to determine whether this consideration and\nthe process that led to it are adequate, or whether the consideration\nundervalues the Company.\n\nIf you believe that this transaction undervalues the Company and/or if you\nwould like to discuss your legal rights regarding the proposed sale, you may,\nwithout obligation or cost to you, e-mail or call KSF Managing Partner Lewis\nS. Kahn (lewis.kahn@ksfcounsel.com (mailto:lewis.kahn@ksfcounsel.com) ) toll\nfree at any time at 855-768-1857, or visit\nhttps://www.ksfcounsel.com/cases/nasdaqgs-cnta/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-cnta%2F&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-cnta%2F&index=3&md5=95940d95821b1c759fcaed8661702e92)\nto learn more.\n\nTo learn more about KSF, whose partners include the Former Louisiana Attorney\nGeneral, visit www.ksfcounsel.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=www.ksfcounsel.com&index=4&md5=5cc5022a091d893e3be952fb1d2b5632)\n.\n\nCONNECT WITH US: Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2Fprofile.php%3Fid%3D61575733915628&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=Facebook&index=5&md5=009525908612bdb13bfd3b08e8134b0d)\n|| Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fkahn_swick_and_foti%2F&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=Instagram&index=6&md5=76b1e01254a4d12b783d1febd2950eea)\n|| YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2F%40kahnswickandfoti&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=YouTube&index=7&md5=a3b6e2ea299be4d1b85482d5a11867ce)\n|| TikTok\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.tiktok.com%2F%40kahn.swick.foti&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=TikTok&index=8&md5=25837fc0567c10bcde6b36a1007c0dfe)\n|| LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fksfcounsel&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=LinkedIn&index=9&md5=51e539b0c261e632c28dda479badc93b)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260511798910/en/\n(https://www.businesswire.com/news/home/20260511798910/en/)\n\nKahn Swick & Foti, LLC\n\nLewis Kahn, Managing Partner\n\nlewis.kahn@ksfcounsel.com \n(mailto:lewis.kahn@ksfcounsel.com) \n855-768-1857\n\n1100 Poydras St., Suite 960\n\nNew Orleans, LA 70163\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw1C23tMa","title":"Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA","author":"Business Wire","ticker":"LLY","created":"2026-05-11T16:43:00.180Z","tickers":["LLY","260Y"],"exchange":"NYSE","article_body":"Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC\nInvestigates Adequacy of Price and Process in Proposed Sale of Centessa\nPharmaceuticals plc - CNTA\n\nFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law\nfirm of Kahn Swick & Foti\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com%2F&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=Kahn+Swick+%26amp%3B+Foti&index=1&md5=12d2e9ac3e8743bd5987953e4d50830a)\n, LLC (“KSF”) are investigating the proposed sale of Centessa\nPharmaceuticals\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-cnta%2F&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=Centessa+Pharmaceuticals&index=2&md5=6f6416b8ec8eaac673eb5ba2fe73b6b3)\nplc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of\nthe proposed transaction, shareholders of Centessa will receive $38.00 in cash\nper share plus one non-transferrable contingent value right entitling the\nholder to receive up to an aggregate of $9.00 subject to the achievement of\ncertain milestones. KSF is seeking to determine whether this consideration and\nthe process that led to it are adequate, or whether the consideration\nundervalues the Company.\n\nIf you believe that this transaction undervalues the Company and/or if you\nwould like to discuss your legal rights regarding the proposed sale, you may,\nwithout obligation or cost to you, e-mail or call KSF Managing Partner Lewis\nS. Kahn (lewis.kahn@ksfcounsel.com (mailto:lewis.kahn@ksfcounsel.com) ) toll\nfree at any time at 855-768-1857, or visit\nhttps://www.ksfcounsel.com/cases/nasdaqgs-cnta/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-cnta%2F&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-cnta%2F&index=3&md5=95940d95821b1c759fcaed8661702e92)\nto learn more.\n\nTo learn more about KSF, whose partners include the Former Louisiana Attorney\nGeneral, visit www.ksfcounsel.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=www.ksfcounsel.com&index=4&md5=5cc5022a091d893e3be952fb1d2b5632)\n.\n\nCONNECT WITH US: Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2Fprofile.php%3Fid%3D61575733915628&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=Facebook&index=5&md5=009525908612bdb13bfd3b08e8134b0d)\n|| Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fkahn_swick_and_foti%2F&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=Instagram&index=6&md5=76b1e01254a4d12b783d1febd2950eea)\n|| YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2F%40kahnswickandfoti&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=YouTube&index=7&md5=a3b6e2ea299be4d1b85482d5a11867ce)\n|| TikTok\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.tiktok.com%2F%40kahn.swick.foti&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=TikTok&index=8&md5=25837fc0567c10bcde6b36a1007c0dfe)\n|| LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fksfcounsel&esheet=54533548&newsitemid=20260511798910&lan=en-US&anchor=LinkedIn&index=9&md5=51e539b0c261e632c28dda479badc93b)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260511798910/en/\n(https://www.businesswire.com/news/home/20260511798910/en/)\n\nKahn Swick & Foti, LLC\n\nLewis Kahn, Managing Partner\n\nlewis.kahn@ksfcounsel.com \n(mailto:lewis.kahn@ksfcounsel.com) \n855-768-1857\n\n1100 Poydras St., Suite 960\n\nNew Orleans, LA 70163\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-11T16:43:00.226662655Z","server_sent_at_ms":1778517780226},"received_at":"2026-05-11T16:43:00.376Z","source_url":"https://www.businesswire.com/news/home/20260511798910/en/"},"analysis":{"id":"22300","press_release_id":"30121","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Kahn Swick & Foti, LLC is investigating the proposed sale of Centessa Pharmaceuticals to Eli Lilly to determine if the consideration and process are adequate for Centessa shareholders.\n\nThe terms of the proposed transaction include $38.00 in cash per share plus one non-transferrable contingent value right of up to $9.00 per share.\n\nThis release is a solicitation for Centessa investors to contact the firm and is not an issuer disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Charles C. Foti, Jr.","role":"Former Attorney General of Louisiana"},{"name":"Lewis S. Kahn","role":"Managing Partner"}],"products":[],"companies":[{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff law firm"},{"name":"Centessa Pharmaceuticals plc","ticker":"CNTA","relationship":"target"},{"name":"Eli Lilly and Company","ticker":"LLY","relationship":"acquirer"}],"dollarAmounts":[{"amount":"$38.00","context":"cash per share offered in proposed sale"},{"amount":"$9.00","context":"contingent value right per share"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Kahn Swick & Foti regarding the proposed sale of Centessa Pharmaceuticals. This is a boilerplate investigation announcement seeking shareholders, not an issuer disclosure or a material court ruling."},"tickerRelevance":{"others":[{"ticker":"CNTA","relevance":"target"}],"primary":"LLY"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mega-cap","eventGravity":"law-firm-solicitation"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kahn Swick & Foti, LLC is investigating the proposed sale of Centessa Pharmaceuticals to Eli Lilly to determine if the consideration and process are adequate for Centessa shareholders.\n\nThe terms of the proposed transaction include $38.00 in cash per share plus one non-transferrable contingent value right of up to $9.00 per share.\n\nThis release is a solicitation for Centessa investors to contact the firm and is not an issuer disclosure.","key_figures":null,"named_entities":{"people":[{"name":"Charles C. Foti, Jr.","role":"Former Attorney General of Louisiana"},{"name":"Lewis S. Kahn","role":"Managing Partner"}],"products":[],"companies":[{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff law firm"},{"name":"Centessa Pharmaceuticals plc","ticker":"CNTA","relationship":"target"},{"name":"Eli Lilly and Company","ticker":"LLY","relationship":"acquirer"}],"dollarAmounts":[{"amount":"$38.00","context":"cash per share offered in proposed sale"},{"amount":"$9.00","context":"contingent value right per share"}]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:a76fb3b19e8e8b7b","schema_hash":"sha256:8658c370b800cf3d","created_at":"2026-05-11T16:44:48.486Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"mega-cap","eventGravity":"law-firm-solicitation"}},"durationMs":108108,"modelName":"george-droid-qwen-72b"}}